Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1635-1640, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azzazy, H. M. E.
Right arrow Articles by Christenson, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azzazy, H. M. E.
Right arrow Articles by Christenson, R. H.
Related Collections
Right arrow Laboratory Management
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1997;43:1635-1640.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Multicenter study of Abbott AxSYM® Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors

Hassan M. E. Azzazy1,2,a, Show-Hong Duh1, Andrew Maturen3, Elisabeth Schaller3, Leslie Shaw4, Robert Grimaldi5, Gloria Shock6 and Robert H. Christenson1,2

1 Departments of Pathology

2 Medical & Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201.

3 Rush–Presbyterian–St. Lukes Medical Center, Chicago, IL 60612.

4 Hospital of the University of Pennsylvania, Philadelphia, PA 19104.

5 New England Medical Center, Boston, MA 02111.

6 Abbott Laboratories, Abbott North Park, IL 60064.
a Address correspondence to this author, at: University of Maryland Medical Center, Clinical Pathology, 22 South Greene St., Baltimore, MD 21201; Fax (410) 328-5880; e-mail hazzazy{at}umabnet.ab.umd.edu

Performance characteristics of the Abbott nonpretreatment AxSYM® Digoxin II assay were evaluated for quantification of digoxin at four independent sites. Correlation of digoxin measurements with the Abbott pretreatment AxSYM®, Baxter Stratus® II, Abbott TDx/TDxFLx II®, Abbott IMx®, Emit® 2000, and Beckman Synchron CX® digoxin assays showed acceptable agreement, as indicated by: slope values >0.84, r >0.90, y-intercepts for all comparisons at or below the assay detection limit, and Sy|x ranging between 7.5% and 15.4% of the average digoxin value. Susceptibility to interference from digoxin-like immunoreactive factors (DLIFs) was examined in 233 samples from renal patients, liver disease patients, cord blood, and third-trimester pregnancies; the AxSYM Digoxin II assay demonstrated the least DLIFs interference. DLIF susceptibility for four of the methods was significantly greater (P <0.05) than in the AxSYM Digoxin II assay; susceptibilities of the Stratus II and Emit 2000 methods were similar to the AxSYM Digoxin II assay.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
W. Steimer, C. Muller, and B. Eber
Digoxin Assays: Frequent, Substantial, and Potentially Dangerous Interference by Spironolactone, Canrenone, and Other Steroids
Clin. Chem., March 1, 2002; 48(3): 507 - 516.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.